<p>LPL 金融控股在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度其对 Halozyme Therapeutics, Inc.（NASDAQ:HALO - 免费报告）的持股增加了 36.6%。该公司在该季度额外购买了 55,410 股后，持有 207,003 股生物制药公司的股票。LPL 金融控股在最近一个季度末持有的 Halozyme Therapeutics 的股份约占 0.16%，价值 9,897,000 美元。</p>
<p>获取 <strong>Halozyme Therapeutics</strong> 的提醒：</p>
<p>其他大型投资者最近也对该公司的持股进行了调整。Heck Capital Advisors LLC 在第四季度购买了价值约 29,000 美元的 Halozyme Therapeutics 新股份。CBIZ 投资顾问服务公司在第四季度购买了价值 29,000 美元的 Halozyme Therapeutics 新股份。Smartleaf 资产管理公司在第四季度将其在 Halozyme Therapeutics 的持股增加了 29.2%。Smartleaf 资产管理公司现在拥有 871 股生物制药公司的股票，价值 42,000 美元，此前在该期间又购买了 197 股。Venturi 财富管理公司在第四季度购买了价值约 69,000 美元的 Halozyme Therapeutics 新股份。最后，Parkside 金融银行与信托在第四季度将其在 Halozyme Therapeutics 的股份增加了 21.8%。Parkside 金融银行与信托现在拥有 1,800 股生物制药公司的股票，价值 86,000 美元，此前在上个季度又购买了 322 股。目前 97.79% 的股票由机构投资者持有。</p>
<h2>Halozyme Therapeutics 股价下跌 3.5%</h2>
<p>NASDAQ HALO 周五开盘价为 59.77 美元。Halozyme Therapeutics, Inc.的 12 个月低点为 37.73 美元，12 个月高点为 66.00 美元。该公司的流动比率为 7.80，速动比率为 9.15，债务与股本比率为 4.14。该股票的 50 日移动平均价格为 59.82 美元，200 日移动平均价格为 54.93 美元。该股票的市值为 73.8 亿美元，市盈率为 17.43，市盈增长比率为 0.42，贝塔系数为 1.32。</p>
<p>Halozyme Therapeutics（NASDAQ:HALO - 获取免费报告）最近于 2 月 18 日（星期二）公布了季度财报。该生物制药公司报告季度每股收益为 1.19 美元，超出市场共识预期的 1.17 美元，超出 0.02 美元。该公司季度收入为 2.9801 亿美元，而市场共识预期为 2.8574 亿美元。Halozyme Therapeutics 的净利润率为 43.74%，股本回报率为 157.78%。分析师预计 Halozyme Therapeutics, Inc.在当前财政年度将发布 4.73 美元的每股收益。</p>
<h2>Halozyme Therapeutics 的内部交易</h2>
<p>在相关消息中，SVP Michael J. Labarre 于 2 月 27 日（星期四）出售了 1,697 股该公司的股票，交易价格为 58.28 美元，总价值为 98,901.16 美元。出售后，该高级副总裁现在持有 173,756 股公司股票，价值约为 10,126,499.68 美元。这笔交易代表其持股减少了 0.97%。该出售在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，董事 Jeffrey William Henderson 于 1 月 6 日（星期一）出售了 10,000 股公司的股票，交易价格为 50.01 美元，总交易额为 500,100.00 美元。出售后，该董事现在持有 43,611 股公司股票，价值约为 2,180,986.11 美元。这代表其持股减少了 18.65%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 32,200 股公司股票，价值 1,786,668 美元。内部人士持有公司股票的比例为 2.90%。</p>
<h2>分析师评级调整</h2>
<p>几位分析师对该股票进行了评论。Benchmark 在 2 月 20 日（星期四）的报告中重申了对 Halozyme Therapeutics 的 “买入” 评级，并给出了 75.00 美元的目标价。HC Wainwright 在 3 月 6 日（星期四）的研究报告中重申了对 Halozyme Therapeutics 的 “买入” 评级。Piper Sandler 在 1 月 10 日（星期五）的研究报告中将 Halozyme Therapeutics 的目标价从 52.00 美元上调至 53.00 美元，并给予该公司 “中性” 评级。最后，富国银行将 Halozyme Therapeutics 的目标价从 62.00 美元下调至 57.00 美元，并在 1 月 13 日（星期一）的报告中对该公司设定了 “等权重” 评级。四位股票研究分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat.com 的数据，Halozyme Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 62.78 美元。</p>
<p><strong>查看我们最新的 HALO 股票报告</strong></p>
<h2>Halozyme Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Halozyme Therapeutics, Inc.是一家生物制药技术平台公司，在美国、瑞士、比利时、日本及国际上研究、开发和商业化专有酶和设备。该公司的产品基于专利的重组人透明质酸酶（rHuPH20），可实现可注射生物制剂的输送，如单克隆抗体和其他治疗分子，以及小分子和液体。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Halozyme Therapeutics 更好</li>
<li>如何投资 FAANG 股票</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>如何在购买前评估一只股票</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>5 美元以下的最佳股票</li>
<li>波音在 3 月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Halozyme Therapeutics 吗？</h2>
<p>在考虑 Halozyme Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Halozyme Therapeutics 并不在名单上。</p>
<p>虽然 Halozyme Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

奥洛兹美医疗

LPL金融控股

<p>LPL 金融控股在 2023 年第四季度增持了 Halozyme Therapeutics, Inc.（纳斯达克代码：HALO）36.6%，目前持有 207,003 股，价值约为 990 万美元。其他投资者也调整了他们的持仓，机构持有该股票的比例为 97.79%。Halozyme 的股票目前下跌 3.5%，报 59.77 美元，市值为 73.8 亿美元。该公司报告的季度每股收益为 1.19 美元，超出预期。分析师的评级意见不一，普遍建议买入，价格目标范围在 53 美元到 75 美元之间</p>

<p>LPL Financial LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 207,003 shares of the biopharmaceutical company's stock after buying an additional 55,410 shares during the quarter. LPL Financial LLC owned approximately 0.16% of Halozyme Therapeutics worth $9,897,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>LPL 金融控股在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度其对 Halozyme Therapeutics, Inc.（NASDAQ:HALO - 免费报告）的持股增加了 36.6%。该公司在该季度额外购买了 55,410 股后，持有 207,003 股生物制药公司的股票。LPL 金融控股在最近一个季度末持有的 Halozyme Therapeutics 的股份约占 0.16%，价值 9,897,000 美元。</p>
</div><p>Get <strong>Halozyme Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Halozyme Therapeutics</strong> 的提醒：</p>
</div><p>Other large investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth $29,000. Smartleaf Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $69,000. Finally, Parkside Financial Bank &amp; Trust boosted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank &amp; Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持股进行了调整。Heck Capital Advisors LLC 在第四季度购买了价值约 29,000 美元的 Halozyme Therapeutics 新股份。CBIZ 投资顾问服务公司在第四季度购买了价值 29,000 美元的 Halozyme Therapeutics 新股份。Smartleaf 资产管理公司在第四季度将其在 Halozyme Therapeutics 的持股增加了 29.2%。Smartleaf 资产管理公司现在拥有 871 股生物制药公司的股票，价值 42,000 美元，此前在该期间又购买了 197 股。Venturi 财富管理公司在第四季度购买了价值约 69,000 美元的 Halozyme Therapeutics 新股份。最后，Parkside 金融银行与信托在第四季度将其在 Halozyme Therapeutics 的股份增加了 21.8%。Parkside 金融银行与信托现在拥有 1,800 股生物制药公司的股票，价值 86,000 美元，此前在上个季度又购买了 322 股。目前 97.79% 的股票由机构投资者持有。</p>
</div><h2>Halozyme Therapeutics Trading Down 3.5 %</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 股价下跌 3.5%</h2>
</div><p>NASDAQ HALO opened at $59.77 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock's fifty day moving average price is $59.82 and its 200-day moving average price is $54.93. The stock has a market cap of $7.38 billion, a P/E ratio of 17.43, a P/E/G ratio of 0.42 and a beta of 1.32.</p>
<div class="lb-trans"><p>NASDAQ HALO 周五开盘价为 59.77 美元。Halozyme Therapeutics, Inc.的 12 个月低点为 37.73 美元，12 个月高点为 66.00 美元。该公司的流动比率为 7.80，速动比率为 9.15，债务与股本比率为 4.14。该股票的 50 日移动平均价格为 59.82 美元，200 日移动平均价格为 54.93 美元。该股票的市值为 73.8 亿美元，市盈率为 17.43，市盈增长比率为 0.42，贝塔系数为 1.32。</p>
</div><p>Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Halozyme Therapeutics（NASDAQ:HALO - 获取免费报告）最近于 2 月 18 日（星期二）公布了季度财报。该生物制药公司报告季度每股收益为 1.19 美元，超出市场共识预期的 1.17 美元，超出 0.02 美元。该公司季度收入为 2.9801 亿美元，而市场共识预期为 2.8574 亿美元。Halozyme Therapeutics 的净利润率为 43.74%，股本回报率为 157.78%。分析师预计 Halozyme Therapeutics, Inc.在当前财政年度将发布 4.73 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Halozyme Therapeutics</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 的内部交易</h2>
</div><p>In related news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,200 shares of company stock worth $1,786,668. Insiders own 2.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，SVP Michael J. Labarre 于 2 月 27 日（星期四）出售了 1,697 股该公司的股票，交易价格为 58.28 美元，总价值为 98,901.16 美元。出售后，该高级副总裁现在持有 173,756 股公司股票，价值约为 10,126,499.68 美元。这笔交易代表其持股减少了 0.97%。该出售在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，董事 Jeffrey William Henderson 于 1 月 6 日（星期一）出售了 10,000 股公司的股票，交易价格为 50.01 美元，总交易额为 500,100.00 美元。出售后，该董事现在持有 43,611 股公司股票，价值约为 2,180,986.11 美元。这代表其持股减少了 18.65%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 32,200 股公司股票，价值 1,786,668 美元。内部人士持有公司股票的比例为 2.90%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several analysts have commented on the stock. Benchmark restated a &#34;buy&#34; rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright restated a &#34;buy&#34; rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Piper Sandler lifted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a &#34;neutral&#34; rating in a research report on Friday, January 10th. Finally, Wells Fargo &amp; Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an &#34;equal weight&#34; rating for the company in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $62.78.</p>
<div class="lb-trans"><p>几位分析师对该股票进行了评论。Benchmark 在 2 月 20 日（星期四）的报告中重申了对 Halozyme Therapeutics 的 “买入” 评级，并给出了 75.00 美元的目标价。HC Wainwright 在 3 月 6 日（星期四）的研究报告中重申了对 Halozyme Therapeutics 的 “买入” 评级。Piper Sandler 在 1 月 10 日（星期五）的研究报告中将 Halozyme Therapeutics 的目标价从 52.00 美元上调至 53.00 美元，并给予该公司 “中性” 评级。最后，富国银行将 Halozyme Therapeutics 的目标价从 62.00 美元下调至 57.00 美元，并在 1 月 13 日（星期一）的报告中对该公司设定了 “等权重” 评级。四位股票研究分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat.com 的数据，Halozyme Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 62.78 美元。</p>
</div><p><strong>View Our Latest Stock Report on HALO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 HALO 股票报告</strong></p>
</div><h2>Halozyme Therapeutics Profile</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.</p>
<div class="lb-trans"><p>Halozyme Therapeutics, Inc.是一家生物制药技术平台公司，在美国、瑞士、比利时、日本及国际上研究、开发和商业化专有酶和设备。该公司的产品基于专利的重组人透明质酸酶（rHuPH20），可实现可注射生物制剂的输送，如单克隆抗体和其他治疗分子，以及小分子和液体。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Halozyme Therapeutics</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>Best Stocks Under $5.00</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Halozyme Therapeutics 更好</li>
<li>如何投资 FAANG 股票</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>如何在购买前评估一只股票</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>5 美元以下的最佳股票</li>
<li>波音在 3 月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SEFMTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=HALO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Halozyme Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Halozyme Therapeutics 吗？</h2>
</div><p>Before you consider Halozyme Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Halozyme Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Halozyme Therapeutics 并不在名单上。</p>
</div><p>While Halozyme Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Halozyme Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LPL 金融控股公司增加了在奥洛兹美医疗公司（NASDAQ:HALO）的持股量